Role of 68Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide
10.1007/s13139-019-00629-3
- Author:
Abhishek JHA
1
;
Mayank PATEL
;
Eva BAKER
;
Melissa K. GONZALES
;
Alexander LING
;
Corina MILLO
;
Marianne KNUE
;
Ali Cahid CIVELEK
;
Karel PACAK
Author Information
1. Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Building 10, CRC, 1E-3140, 10 Center Drive, MSC-1109, Bethesda, MD, 20892-1109, USA
- Publication Type:Case Report
- From:Nuclear Medicine and Molecular Imaging
2020;54(1):48-52
- CountryRepublic of Korea
- Language:English
-
Abstract:
We describe an unusual case of a 42-year-old female with an unresectable succinate dehydrogenase subunit B (SDHB)-related pterygopalatine fossa paraganglioma. She underwent somatostatin receptor imaging with 68Ga-DOTA(0)-Tyr(3)-octreotate (68Ga-DOTATATE) positron emission tomography/computed tomography (PET/CT), which showed uptake in the above mentioned tumor. Hence, the patient was started on octreotide, a cold somatostatin analog, and responded with tumor stabilization and improvement of clinical symptoms for 36 months since initiation of octreotide therapy. This case demonstrates the role of 68Ga-DOTATATE PET/CT in diagnostic localization and its subsequent role in treatment using cold somatostatin analog as a potential choice of therapy in the management of paraganglioma in an unusual location with limited therapeutic options.
